Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BXJ7
UPID:
AMNLS_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BXJ7; Q6UX83
Background:
Protein amnionless is a crucial membrane-bound component of the endocytic receptor complex formed with AMN and CUBN, playing a pivotal role in vitamin B12 absorption and protein transport in the kidney. Its involvement in the glycosylation and trafficking of CUBN to the cell surface underscores its essential function in cellular processes.
Therapeutic significance:
The protein's link to Imerslund-Grasbeck syndrome 2, a disorder characterized by vitamin B12 deficiency, highlights its therapeutic potential. Understanding the role of Protein amnionless could open doors to potential therapeutic strategies for treating this rare autosomal recessive disorder.